pharma · Schizophrenia · Autosomal Recessive Polycystic Kidney Disease
Otsuka Beijing Research
Otsuka Beijing Research Institute
Otsuka Beijing Research clinical programs — 7 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- CN
- Programs
- 33
- Drugs
- 25
- Patents
- 0
Otsuka Beijing Research projects
7 ClinicalTrials.gov programs sponsored by Otsuka Beijing Research.
Otsuka Beijing Research has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
100 mg Delamanid
Otsuka Beijing Research Institute
Multidrug Resistant Tuberculosis
1 trial -
323-201-00009
Otsuka Beijing Research Institute
Tuberculosis
1 trial -
A Trial to Examine the Effects of MSP-2020 on Brain Activity in Healthy Adults
Otsuka Beijing Research Institute
Incomplete Response - Major Depressive Disorder (IR-MDD)
1 trial -
OPB-31121
Otsuka Beijing Research Institute
Non-Hodgkin's Lymphoma(NHL)
1 trial -
OPC-108459
Otsuka Beijing Research Institute
Atrial Fibrillation
1 trial -
Tolvaptan 15mg or 30mg or 60mg or Placebo
Otsuka Beijing Research Institute
Healthy
1 trial -
VIS171-103
Otsuka Beijing Research Institute
Systemic lupus erythematosus, Immune-mediated focal segmental glomerulosclerosis, Alopecia Areata
1 trial
Frequently asked questions
How many clinical projects does Otsuka Beijing Research have?
7 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.